Literature DB >> 27028797

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.

Federica Del Chierico1, Valerio Nobili2,3, Pamela Vernocchi1, Alessandra Russo1, Cristiano De Stefanis3, Daniela Gnani3, Cesare Furlanello4, Alessandro Zandonà4, Paola Paci5,6, Giorgio Capuani7, Bruno Dallapiccola8, Alfredo Miccheli7, Anna Alisi3, Lorenza Putignani1,9.   

Abstract

There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by gut microbiota. Therefore, we investigated its modifications in pediatric NAFLD patients using targeted metagenomics and metabolomics. Stools were collected from 61 consecutive patients diagnosed with nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), or obesity and 54 healthy controls (CTRLs), matched in a case-control fashion. Operational taxonomic units were pyrosequenced targeting 16S ribosomal RNA and volatile organic compounds determined by solid-phase microextraction gas chromatography-mass spectrometry. The α-diversity was highest in CTRLs, followed by obese, NASH, and NAFL patients; and β-diversity distinguished between patients and CTRLs but not NAFL and NASH. Compared to CTRLs, in NAFLD patients Actinobacteria were significantly increased and Bacteroidetes reduced. There were no significant differences among the NAFL, NASH, and obese groups. Overall NAFLD patients had increased levels of Bradyrhizobium, Anaerococcus, Peptoniphilus, Propionibacterium acnes, Dorea, and Ruminococcus and reduced proportions of Oscillospira and Rikenellaceae compared to CTRLs. After reducing metagenomics and metabolomics data dimensionality, multivariate analyses indicated a decrease of Oscillospira in NAFL and NASH groups and increases of Ruminococcus, Blautia, and Dorea in NASH patients compared to CTRLs. Of the 292 volatile organic compounds, 26 were up-regulated and 2 down-regulated in NAFLD patients. Multivariate analyses found that combination of Oscillospira, Rickenellaceae, Parabacteroides, Bacteroides fragilis, Sutterella, Lachnospiraceae, 4-methyl-2-pentanone, 1-butanol, and 2-butanone could discriminate NAFLD patients from CTRLs. Univariate analyses found significantly lower levels of Oscillospira and higher levels of 1-pentanol and 2-butanone in NAFL patients compared to CTRLs. In NASH, lower levels of Oscillospira were associated with higher abundance of Dorea and Ruminococcus and higher levels of 2-butanone and 4-methyl-2-pentanone compared to CTRLs.
CONCLUSION: An Oscillospira decrease coupled to a 2-butanone up-regulation and increases in Ruminococcus and Dorea were identified as gut microbiota signatures of NAFL onset and NAFL-NASH progression, respectively. (Hepatology 2017;65:451-464).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27028797     DOI: 10.1002/hep.28572

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  184 in total

Review 1.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

2.  Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study.

Authors:  Federica Del Chierico; Melania Manco; Simone Gardini; Valerio Guarrasi; Alessandra Russo; Marzia Bianchi; Valentina Tortosa; Andrea Quagliariello; Blegina Shashaj; Danilo Fintini; Lorenza Putignani
Journal:  Acta Diabetol       Date:  2021-03-22       Impact factor: 4.280

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

Review 4.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

5.  An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.

Authors:  Marialena Mouzaki; Rohit Loomba
Journal:  Curr Treat Options Gastroenterol       Date:  2020-05-02

6.  Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.

Authors:  Suzanne R Sharpton; Bharat Maraj; Emily Harding-Theobald; Eric Vittinghoff; Norah A Terrault
Journal:  Am J Clin Nutr       Date:  2019-07-01       Impact factor: 7.045

Review 7.  Gut microbiome and liver disease.

Authors:  Naga S Betrapally; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

Review 8.  Gut microbiota in human metabolic health and disease.

Authors:  Yong Fan; Oluf Pedersen
Journal:  Nat Rev Microbiol       Date:  2020-09-04       Impact factor: 60.633

9.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

10.  Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Min-Tzu Lo; Amy Liu; Ricki Bettencourt; Veeral H Ajmera; Shirin Bassirian; Jonathan Hooker; Ethan Sy; Lisa Richards; Nicholas Schork; Bernd Schnabl; David A Brenner; Claude B Sirlin; Chi-Hua Chen; Rohit Loomba
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.